T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Kearny Financial
KRNY
$604M
| $50.7M | ﹤0.01% |
3,827,752
-1,434
| -0% | -$18.9K |
|
1002
Immuneering
IMRX
$336M
| $50.7M | ﹤0.01% |
3,188,505
+74,480
| +2% | +$1.81M |
|
|
ABMD
1003
DELISTED
Abiomed Inc
ABMD
| $50.7M | ﹤0.01% |
141,024
-442
| -0.3% | -$149K |
|
1004
Telephone and Data Systems
TDS
$4.03B
| $50.3M | ﹤0.01% |
2,494,802
-775,318
| -24% | -$15.1M |
|
1005
Synaptics
SYNA
$4.3B
| $50.3M | ﹤0.01% |
173,604
+157,523
| +980% | +$37.6M |
|
1006
Marqeta
MQ
$1.71B
| $50.2M | ﹤0.01% |
+730,800
| New | +$65.4M |
|
|
PRFT
1007
DELISTED
Perficient Inc
PRFT
| $49.9M | ﹤0.01% |
385,776
+25
| +0% | +$3.29K |
|
|
HCCI
1008
DELISTED
Heritage-Crystal Clean, Inc.
HCCI
| $49.7M | ﹤0.01% |
1,552,185
-68,825
| -4% | -$2.24M |
|
|
FRGI
1009
DELISTED
Fiesta Restaurant Group, Inc.
FRGI
| $49.6M | ﹤0.01% |
4,500,831
-162,075
| -3% | -$1.73M |
|
1010
Blackstone
BX
$112B
| $49.5M | ﹤0.01% |
382,774
+5,020
| +1% | +$669K |
|
1011
Brown-Forman Class B
BF.B
$12.8B
| $49.3M | ﹤0.01% |
677,117
-14,520
| -2% | -$1.03M |
|
|
CHCT
1012
Community Healthcare Trust
CHCT
$433M
| $49.1M | ﹤0.01% |
1,039,016
+65,361
| +7% | +$3M |
|
|
REVHU
1013
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Units
REVHU
| $49.1M | ﹤0.01% |
4,982,268
-77,009
| -2% | -$764K |
|
1014
Arista Networks
ANET
$257B
| $48.8M | ﹤0.01% |
1,359,008
-832
| -0.1% | -$24.8K |
|
1015
ACI Worldwide
ACIW
$5.33B
| $48.7M | ﹤0.01% |
1,402,424
-55,153
| -4% | -$1.77M |
|
1016
Innovative Industrial Properties
IIPR
$1.67B
| $48.6M | ﹤0.01% |
184,971
+23,732
| +15% | +$6.09M |
|
1017
Allogene Therapeutics
ALLO
$683M
| $48.5M | ﹤0.01% |
3,251,528
-1,087,463
| -25% | -$19.2M |
|
|
BCYC
1018
Bicycle Therapeutics
BCYC
$279M
| $48.5M | ﹤0.01% |
+796,014
| New | +$43.9M |
|
1019
Expeditors International
EXPD
$24B
| $48.3M | ﹤0.01% |
359,968
-9,335
| -3% | -$1.17M |
|
1020
Nasdaq
NDAQ
$54.6B
| $48.3M | ﹤0.01% |
689,904
-15,192
| -2% | -$1.03M |
|
1021
Phillips 66
PSX
$92.8B
| $48.3M | ﹤0.01% |
665,966
-23,943
| -3% | -$1.81M |
|
1022
MeiraGTx Holdings
MGTX
$1.17B
| $48M | ﹤0.01% |
2,020,745
+17,725
| +0.9% | +$339K |
|
1023
Williams Companies
WMB
$90.1B
| $47.9M | ﹤0.01% |
1,839,897
-69,764
| -4% | -$1.93M |
|
1024
Rocket Pharmaceuticals
RCKT
$367M
| $47.9M | ﹤0.01% |
2,192,894
-691,532
| -24% | -$18.9M |
|
|
DENN
1025
DELISTED
Denny's
DENN
| $47.6M | ﹤0.01% |
2,977,847
-162,679
| -5% | -$2.49M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.